These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 32415802

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Exercise anaerobic threshold and ventilatory efficiency identify heart failure patients for high risk of early death.
    Gitt AK, Wasserman K, Kilkowski C, Kleemann T, Kilkowski A, Bangert M, Schneider S, Schwarz A, Senges J.
    Circulation; 2002 Dec 10; 106(24):3079-84. PubMed ID: 12473555
    [Abstract] [Full Text] [Related]

  • 24. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
    McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, Garg J, Lokhnygina Y, Holman RR, Peterson ED, Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group.
    JAMA Cardiol; 2016 May 01; 1(2):126-35. PubMed ID: 27437883
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
    Yamada H, Tanaka A, Kusunose K, Amano R, Matsuhisa M, Daida H, Ito M, Tsutsui H, Nanasato M, Kamiya H, Bando YK, Odawara M, Yoshida H, Murohara T, Sata M, Node K, PROLOGUE Study Investigators.
    Cardiovasc Diabetol; 2017 May 11; 16(1):63. PubMed ID: 28490337
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
    Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Gouda M, Iijima H, Watanabe Y.
    Diabetes Obes Metab; 2018 Feb 11; 20(2):453-457. PubMed ID: 28786530
    [Abstract] [Full Text] [Related]

  • 28. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.
    Spertus JA, Birmingham MC, Nassif M, Damaraju CV, Abbate A, Butler J, Lanfear DE, Lingvay I, Kosiborod MN, Januzzi JL.
    Nat Med; 2022 Apr 11; 28(4):809-813. PubMed ID: 35228753
    [Abstract] [Full Text] [Related]

  • 29. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
    Tanaka A, Inoue T, Kitakaze M, Oyama J, Sata M, Taguchi I, Shimizu W, Watada H, Tomiyama H, Ako J, Sakata Y, Anzai T, Uematsu M, Suzuki M, Eguchi K, Yamashina A, Saito Y, Sato Y, Ueda S, Murohara T, Node K.
    Cardiovasc Diabetol; 2016 Apr 04; 15():57. PubMed ID: 27044332
    [Abstract] [Full Text] [Related]

  • 30. Short-term outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting.
    Shao YL, Yee KH, Koh SK, Wong YF, Yeoh LY, Low S, Sum CF.
    Singapore Med J; 2018 May 04; 59(5):251-256. PubMed ID: 29022040
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?
    Fudim M, Kelly JP, Jones AD, AbouEzzeddine OF, Ambrosy AP, Greene SJ, Reddy YNV, Anstrom KJ, Alhanti B, Lewis GD, Hernandez AF, Felker GM.
    Am Heart J; 2020 Feb 04; 220():97-107. PubMed ID: 31805424
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Ventilatory response to exercise improves risk stratification in patients with chronic heart failure and intermediate functional capacity.
    Corrà U, Mezzani A, Bosimini E, Scapellato F, Imparato A, Giannuzzi P.
    Am Heart J; 2002 Mar 04; 143(3):418-26. PubMed ID: 11868046
    [Abstract] [Full Text] [Related]

  • 39. SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes.
    Bajaj HS, Brown RE, Bhullar L, Sohi N, Kalra S, Aronson R.
    Diabetes Metab; 2018 Dec 04; 44(6):493-499. PubMed ID: 30149145
    [Abstract] [Full Text] [Related]

  • 40. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
    Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F, Rodriguez-Cordero A, Zafar MU, Fergus I, Atallah-Lajam F, Contreras JP, Varley C, Moreno PR, Abascal VM, Lala A, Tamler R, Sanz J, Fuster V, Badimon JJ, EMPA-TROPISM (ATRU-4) Investigators.
    J Am Coll Cardiol; 2021 Jan 26; 77(3):243-255. PubMed ID: 33197559
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.